Background. Designing trials to reduce treatment duration is important in several therapeutic areas, including TB and antibiotics. We recently proposed a new randomised trial design to overcome some of the limitations of standard two-arm non-inferiority trials. This DURATIONS design involves randomising patients to a number of duration arms, and modelling the so-called 'duration-response curve'. This article investigates the operating characteristics (type-1 and type-2 errors) of different statistical methods of drawing inference from the estimated curve.
Introduction
In several therapeutic areas, it is important to identify the optimal duration of treatment, defined as the shortest duration providing an acceptable efficacy. For example, reducing antibiotic treatment duration has been suggested as a way of combatting antimicrobial resistance 1 , but this has to be done while maintaining high cure rates. Furthermore, shorter treatment durations often increase adherence, reduce side-effects and will be more costeffective, provided they do not lead to an increased risk of relapse.
We recently proposed the DURATIONS randomised trial design 2 as an improvement over standard non-inferiority trials 3 for identifying the shortest acceptable treatment duration 4 . Its main attraction is that it does not involve selection of a single shorter duration to test against a control, which is often chosen based on very limited prior evidence; instead, patients are randomised to multiple durations, enabling the relationship between duration and response to be directly estimated using pre-specified flexible regression models. Randomising 500 patients to 5-7 durations enables the underlying duration-response curve to be estimated within 5% average absolute error in 95% of simulations 2 .
The DURATIONS design moves away from a binary hypothesis testing paradigm, so that the trial outcome is not a treatment difference between two fixed durations, but rather the whole estimated duration-response curve. In applications, we wish to use this curve to inform decision-making, and hence it is essential to understand the properties of various ways of drawing inference from the curve. This article therefore first defines DURATION-design quantities analogous to power and type-I error, and then compares different strategies of inference for these quantities, through extensive simulations.
Drawing inference from the duration-response curve
Suppose there is a treatment that is known to be highly effective compared to placebo, and that is usually prescribed as standard-of-care to patients with a particular disease or condition for a fixed course duration; examples include antibiotics for bacterial infections and direct acting antivirals against Hepatitis C. Additionally, suppose the recommended treatment course is days, although we believe that shorter durations might be similarly effective, so that we suspect the shortest effective duration might be as small as .
Now, suppose we want to design a trial to identify the shortest effective duration and assume that the primary outcome of the trial is cure, a binary variable equal to 1 if the patient recovers from their condition or 0 otherwise. Using a DURATIONS randomised trial design 2 we randomise N, say 500, patients to multiple, e.g. 7, duration arms, between and including and . After observing the responses, we fit a pre-specified fractional polynomial logistic model with cure as outcome and duration as the only covariate, with up to two polynomial terms. This gives us an estimated duration-response curve, similar to the black curve in Figure 1 .
When provided with this curve, how should clinicians and policy-makers choose what is the 'optimal' duration to prescribe? A simple choice is to target the duration leading to at most a fixed risk loss of efficacy (difference ) compared to the control (maximum) duration, e.g.
5% less. Hence, if the estimated control cure rate at was , our objective would be to find the minimum duration * corresponding to a cure rate of at least * = − .
The rationale for this choice closely corresponds to that for the choice of margin in noninferiority trials, i.e. it answers the question "what is the minimum treatment efficacy that we would be happy to tolerate, given the ancillary advantages of the active treatment (i.e. of reducing treatment duration)"?
In this section we propose different ways of estimating such a * from the duration-response curve, and investigate their operating characteristics in Section 3. We extend to different possible objectives in Section 4.
Model confidence bands
The simplest approach is to extrapolate * from the duration-response curve, selecting the duration at which * = − . However, the fitted curve is just the most likely estimated from the sample data. Thus, there is a non-negligible probability that the true * is below this value. Instead, we will typically wish to keep type-1 error below 2.5%, so that we do not recommend a duration that is not long enough more than 2.5% of the time.
The first and most naïve method of controlling type-1 error uses the lower bound of the pointwise confidence bands around the curve, looking for the duration * satisfying * − 1.96 * = − . To avoid recommending non-integer durations, which might make little sense in applications, we round the selected duration * up to the next whole number;
hence, we select the duration that satisfies:
With being the set of integer durations.
Delta method CI
To compare two specific points on the duration-response curve, we need to estimate a confidence interval around the difference in outcome between the two points. In our application, we really want to compare each shorter duration against the longest duration ; hence, we want to estimate the confidence intervals around − for every (including any integer duration randomised to or not randomised to below ). Let us call these confidence intervals = , , with being the confidence level. These can be estimated using the delta-method, which gives a good approximation based on Taylor series expansions (details in Appendix A). Inference can then be drawn by selecting the minimum duration * for which * < .
Bootstrap CI
Alternatively, rather than relying on these approximations, given the observed dataset with N observations we can sample with replacement N observations M times, generating M bootstrap samples. We then fit the fractional polynomial model on each of the M datasets and estimate in each bootstrap sample − for every . We then calculate bootstrap confidence intervals around these quantities, and use these to choose the optimal * .
Bootstrap Duration CI
Another way of using bootstrapping is to directly estimate a confidence interval around * .
M bootstrap samples are selected similarly to Section 2.3, but instead of estimating − in each sample we estimate the corresponding * , denoted * , with m indexing the bootstrap sample. Then a bootstrap confidence interval ( * , , * , ) can be constructed from the bootstrap mean estimate * and its standard error, and the recommended duration would be:
= min ( > * , ) Table 1 provides an overview of the properties of different methods. The attractiveness of the confidence bands method comes from its simplicity, as it is probably the method most researchers would naturally use to estimate * from the duration-response curve. However, it has several limitations, the most important being that the pointwise confidence bands for the curve are not the same as the confidence interval for the difference between two specific points on the curve.
Theoretical comparison of methods
While the delta method (2.2) addresses this problem, it is affected by at least one other issue, at least when using fractional polynomials 5 as the flexible regression method: specifically, that model selection variability should be taken into account 6 7 , in our application, with a single covariate and a reasonable number of expected events, a modified algorithm selecting exactly two polynomial terms rather than a maximum of two is likely to be preferable, and makes it easier to satisfy the assumption that the model used is approximately correct. Henceforth, we refer to this method as the modified fractional polynomial analysis.
Simulations
We compared the methods presented above in a simulation study designed using the recently proposed ADEMP framework 8 .
Aims
The main aim is to compare different strategies of drawing inference from the durationresponse curve. Specific questions are: are bootstrap methods necessary, or does the simpler delta-method suffice? Is the modified fractional polynomial analysis preferable? How problematic is the multiplicity issue with the bootstrap CI method?
Data-generating mechanisms
The DURATIONS design aims to be resilient to the true underlying duration-response relationship. Consequently, we generate data under sixteen different scenarios that are listed and plotted in the additional material online, including the eight scenarios in (Quartagno et al, 2018 ). These reflect a wide range of possible duration-response relationships, including both those generated by fractional polynomials and those generated from sigmoid functions (which are not strictly within the fractional polynomial paradigm). For comparisons, we rescale the x-axis so that the minimum duration considered ( ) is 8 days, and the maximum is 20 days, with 7 randomised arms evenly spread between them (8, 10, 12, 14, 16, 18, 20) . We generate 1000 data sets from each scenario of N=500 individuals. Using the same process, we additionally generate 200 datasets of N=750 and N=1000 individuals, to explore the sensitivity of results to total sample size.
Estimation targets
We assume the estimation target of interest is the duration * leading to a cure rate that is % less than at the longest (and currently used) duration . This approximately corresponds to the shortest duration non-inferior to standard-of-care within a non-inferiority margin on the risk difference scale. In our base case, we consider = 10%, a margin that has been recommended for example by FDA for non-inferiority trials of antibiotics for adult bacterial community acquired pneumonia 9 . However, as in some applications this may be considered too large a margin, we additionally explore the sensitivity of results using = 5%. This risk difference based estimation target might not be optimal in all applications, and hence in Section 4 we propose different estimation targets.
Methods
We compare the four different methods of estimating * described above. For the bootstrap methods, we use M=500 replications. For method 2.3, we build confidence intervals using the BCa method 10 , which is based on the percentiles of the bootstrap distribution, but with adjustments to account for both bias and skewness. For method 2.4, we use the percentile confidence interval instead, as BCa is not applicable in some scenarios where the bootstrap distribution is truncated at 8 days. Additionally, we compare the standard (i.e. selecting up to two polynomial terms) and modified (i.e. selecting exactly two terms) fractional polynomial algorithms for method 2.4.
Performance measures
The choice of performance measures is not straightforward. Unlike most randomised trial designs, our DURATIONS randomised design does not define a null hypothesis to test. This is because the longest treatment duration we randomise patients to is already known to be (usually highly) effective, and our aim is only to find the most appropriate shorter duration.
Under very simple assumptions, i.e. that the duration-response curve is continuous and monotonic, we know that either there is a duration * in the interval [ ; ] such that * = − , or that even the shortest duration is sufficiently effective, i.e. * = ≥ − .
Given this, and having defined our estimation target, we define three main performance measures of interest:
1) Type-1 Error: in this context we define type-1 error as the probability that our trial ends up recommending a duration * that is insufficiently effective:
2) Full Power: there are several ways to define power compared to standard hypothesis testing. We define full power as the probability that the trial ends up recommending the actual optimal duration, that is the minimum effective (integer) duration:
3) Partial Power: designing a trial to reach high levels of Full Power might be difficult, but one might be interested in simply finding an effective duration that is shorter than the recommended one, even if it is not necessarily the minimum effective duration.
We define the partial power as the probability that our trial identifies one such duration:
Additionally, we measure performance by considering the distribution of all the recommended durations * .
Results
Figure 2 compares type-1 error and partial power across the different methods. It is immediately clear that type-1 error is not adequately controlled under certain scenarios.
These scenarios are mainly those where the curvature at the optimal duration is positive, i.e. those for which steepness of the curve is increasing at the optimal duration. These are arguably not the most likely scenarios in our settings, as we expect to be investigating part of the duration-response curve where the curve is asymptoting; nevertheless, it is preferable to use methods like those in Section 2.3 and 2.4 that provide better inference by taking into account model selection variability. Differences between the two bootstrap methods are less marked ( Table 2) , although type-1 error is generally slightly lower using the bootstrap duration CI method (2.4) .
In terms of analysis model, the modified fractional polynomial method is preferable with regards to type-1 error ( Figure 2 and Table E Figure 3) . However, this figure shows that the difference between the estimated minimum duration and the actual minimum acceptable duration is small (<=1 day) in these scenarios and that the 2.5 th percentiles of recommended durations (and associated cure rate) are actually very close to the optimal duration (and corresponding cure rate).
In terms of power, differences are not as pronounced, and all methods achieve very good partial power (>90%) under most scenarios. Of note, the simulated sample size (N=500) was determined to estimate the duration-response curve within a certain average absolute error (5%), and not to achieve a specific power under any of our scenarios. As expected, full power is always substantially lower, particularly in scenarios where the cure rate at the optimal duration is very close to the minimum acceptable cure rate. Again, differences between different methods are not substantial.
The only scenario where full power exceeds 80% is Scenario 4 ( 
Alternative objectives
In this simulation study, we assumed that the trial objective was to find the minimum duration * such that * ≥ − . This clearly corresponds with standard noninferiority trials designed with margin on the risk difference scale: in both, we assume that if the cure rate in the intervention arm is poorer only within a certain limit, then its secondary advantages make it preferable to the control arm. In this section we discuss different objectives. Some are again in common with standard non-inferiority trials, while others are specific to our design.
Fixed rate
Instead of considering a fixed difference in cure rate compared to control, one might simply want to identify the duration * leading to a specific cure rate * : * = min ( ≥ * )
This may be reasonable when there is good prior information on the expected cure rate at the control duration , although one can never be sure that the population recruited will reflect historical controls. Methods 2.3 and 2.4 could be used as analysis methods for this estimation target.
Fixed risk ratio
Analogously to a standard non-inferiority trial, the margin could also be defined on a relative scale; for example, as the proportion of the cure rate at that should be preserved in order to consider the shorter duration preferable:
For example, if we wanted to preserve 90% of the effect of treatment at , we would choose = 0.9.
The acceptability frontier
While non-inferiority trials naturally have a single non-inferiority margin , in DURATIONS trials it might instead be logical to have different margins for each specific duration . For example, for a duration that is a half of , we might be happy to tolerate a slightly larger than for a duration equal to two thirds of , assuming that advantages of shorter durations generally increase as the duration reduces. Hence, the objective of the trial might be to find the duration * such that:
where ( ) is the function that indicates the acceptable loss in cure rate for each duration .
We call this the Acceptability Frontier, a possible example of which is the grey line in Figure   1 .
Maximum gradient
Instead of targeting a specific cure rate, or difference in cure rate, investigators might be interested in the gradient of the duration-response curve. If we expect the curve to asymptote after a certain duration D*, then we might define such D* as the point after which the gradient of the function is always below a certain threshold : * = min ( ∇ ( ) ≤ , ∀ > )
For example, in the scenarios above, we found that = 2% was a reasonable value for this threshold.
Additional simulations
We performed additional simulations to explore operating characteristics of the bootstrap duration CI method (2.4) with each of these different estimation targets. We analysed the same 1000 datasets generated for the 16 scenarios in our base case simulations, with N=500.
As the target cure rate, we chose in each scenario the value 10% less than the true cure rate at the longest duration. For the fixed risk ratio, we used = 0.9. The acceptability frontier was a linear function, such that the largest acceptable risk difference at was 10%, and at 18 days 5% (Figure 1) . Finally, the maximum acceptable gradient was taken to be 2%. For this last estimation target we did not use method 2.4, but we simply looked at the single point estimate in the data. Results ( Tables D-G in the additional material) show reasonable performance for the first three alternative estimation targets. For the maximum gradient target, type-1 errors are large, and further analysis refinements would be necessary to use this.
Analysis example
Given the simulation results, here we sketch our favoured three-step approach to analysing a DURATIONS trial. First, an acceptability frontier should be defined, answering the question "what would the non-inferiority margin be for a trial comparing the longest duration to each shorter one?". In this example, we assume a reasonable non-inferiority margin is 10% cure rate difference compared to the control duration, as in the base-case scenario of our simulations (Figure 4 ). Second, we run our modified fractional polynomial algorithm to estimate the duration-response curve (black solid line in Figure 4 ). Third, we use the bootstrap (BCa method 10 ) to find the confidence interval either around our estimated optimal duration * or the differences in cure rate from the control at each duration (left and right panel of Figure 4 respectively). In this example, both methods recommend * = 13 days as optimal duration.
Discussion
In this article we have compared different strategies for drawing inference from a durationresponse curve estimated using a DURATIONS randomised trial design. We defined quantities analogous to type-1 error and power in this scenario, and found a method based on bootstrap re-sampling -to estimate the duration associated with a specific cure rate difference from control -has good inferential properties when combined with a modified fractional polynomial analysis method. This is therefore our recommended approach.
One issue with the standard non-inferiority design for identifying optimal treatment duration is the potential for so-called 'bio-creep', i.e. the erosion of efficacy from sequentially testing for non-inferiority shorter durations, iteratively updating the control duration to one previously shown to be non-inferior 11 . One advantage of the DURATIONS design is that it avoids this problem, as all the durations are evaluated in the same trial. Another advantage is its resilience; in a standard non-inferiority trial, whenever a single design parameter turns out to have been badly misjudged, the whole trial can quickly lose power or interpretability. By contrast, the DURATIONS design has been developed to be flexible enough to maintain good properties against a wide range of duration-response curves.
Extensions
Design and analysis of randomised trials often intersect, and hence what is an analysis decision (how to analyse and draw inference from the observed data) also has design implications (how to best design a trial that we aim to analyse in a particular way). Hence, future work will investigate how to design a DURATIONS randomised trial that we aim to analyse with methods presented here.
We focused on binary outcomes, but similar methods could be easily used for continuous and survival outcomes, with the only additional complication of having to derive a suitable estimation target. When developing the target based on the acceptability frontier, we assumed that this frontier was subjectively drawn by the analyst, based on assumptions about the trade-offs between shortening duration and loss of treatment efficacy. An alternative could be to derive the acceptability frontier using available data on the secondary advantages of shorter durations. For example, if the goal was to design a DURATIONS trial in Hepatitis C, the acceptability frontier could be built using data on costs.
Future work could include investigating the effect of including additional covariates in the fractional polynomial model, for example age or sex, if there was evidence that the optimal duration might vary depending on these factors. It could also investigate using an adaptive design, to allow for closure of poorly performing arms (i.e. those at the lowest durations) 4 .
For TB and related settings, where the optimal duration might be investigated for a new drug or new regimen, it is important to investigate the best way to include a formal comparison with an independent control treatment of fixed duration, for example with the standard 6month TB treatment course with rifampicin, isoniazid, pyrazinamide and ethambutol.
Conclusions
We recently proposed a DURATIONS randomised trial design as an alternative to a standard two-arm non-inferiority design when the goal is to optimise treatment duration. Here we have investigated the operating characteristics of various methods of drawing inference from the duration-response curve and found that a method based on bootstrap to estimate a duration associated with a specific cure rate has good properties and is an appealing choice. Using this analysis method, DURATIONS randomised trials could help identify better treatment durations in an optimal way across many illnesses 4 .
Code
The code used for the simulations will be made available on the GitHub page of the first author. Appendix A. Delta Method Confidence Interval.
Suppose we ran our fractional polynomial algorithm estimating our duration-response curve:
where a linear and a quadratic term have been selected by the algorithm, and , , is the vector of estimated model parameters. Our goal is to obtain a confidence interval for the difference in efficacy between two specific durations and . This can be written as a function of model parameters, as: Let be the variance covariance matrix of the three regression parameters, so that approximately:
~ ,
And let the Jacobian of function ( , , ) be the vector of partial derivatives with respect to the three variables:
Then, using the delta method, we have that:
( , , ) = ( ) − ( ) → , , , , , , ,
